Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Treatment with recombinant human -Gal A (rh-GLA) A previous in vitro study on Fabry disease using mouse aortic endothelial cells from -Gal A-deficient mice showed that rh-GLA treatment for 48 hr reduced Gb3 at a dose from 0.160 g/ml 20
Some PK studies report an increased theoretical risk of toxicity with advancing age [62,63,64,65,66,67] due to prolongation of t 1/2 [62, 63], reduced paracetamol clearance [64, 67], increased paracetamol oxidation caused by a reduction in glucuronidation and sulphation capacity [65] or a reduction in liver volume [66]
Product Details Packaging: 5 mg of lyophilized powder in a sterile glass vial Storage: Store at 2-8C (refrigerated)
Morando F, Rosi S, Gola E et al (2014) Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study
Flanagan makes sure your sample has a high enough concentration of platelets to provide effective treatment
US$ 27.34
US$ 20.24
US$ 25.61
US$ 27.61